Haim Zaltzman

Haim Zaltzman's representative experience includes advising:

Hercules Capital in structured and venture debt facilities, including multiple recurring revenue facilities.
Sixth Street on the growth financing for Bourque Logistics.
DailyPay in securing US$100 million to its secured credit facility capacity from Citi.
Wolfspeed on funding agreements worth US$750 million with the US Department of Commerce and a bespoke unsecured customer deposit facility, valued at up to US$2 billion.
Thumbtack in a US$75 million financing from Hercules Capital, Inc. and Silicon Valley Bank.
Blue Owl in TravelPerk’s credit facility of up to US$135 million, together with Blackstone.
Francisco Partners in the US$90 million term loan to Property Finder.
Monroe Capital on the funding of a senior credit facility to support the merger and growth of ParkHub and JustPark.

Hercules Capital in multiple growth facilities for leading technology companies, including the US$100 million debt financing for Pindrop.
Maverick Capital in TensorWave’s up to US$43 million funding round and a US$70 million funding round for SiMa.ai.
Morgan Stanley Tactical Value in a US$100 million growth investment for Clip and a US$401 million investment round for Netskope.
Cheq Lifestyle Technology in its acquisition by Cantaloupe.
Sixth Street Growth on its investment in a €285 million funding round for SumUp.

Ascendis Pharma in a US$150 million royalty funding agreement with Royalty Pharma.
Arcus Biosciences in a US$250 million term loan facility from Hercules Capital.
Health Catalyst in a US$225 million credit facility provided by Silver Point Finance.
BridgeBio Pharma in a US$1.25 billion strategic investment from Blue Owl Capital and Canada Pension Plan Investment Board.
Nevro Corp. in its acquisition of Vyrsa Technologies and a related US$200 million term loan.

SLR Capital Partners in corporate matters related to Vapotherm’s merger.
Bolt Threads in its business combination with Golden Arrow Merger Corp.
Ascendis Pharma in its US$150 million royalty funding agreement with Royalty Pharma.
Rhythm Pharmaceuticals in a US$100 million revenue interest financing with HealthCare Royalty Partners.

Latham & Watkins LLP